DermBiont raises $35.2M Series B to advance two dermatological drugs through PhII
25 Oct 2023
Microbial therapyPhase 2
Boston biotech DermBiont closed a $35.2 million funding round Tuesday to advance development of two of its dermatological topical candidates.
The financing included a $27.1 million Series B and $8.1 million in converting outstanding notes led by Double Point Ventures to take two of its candidates through Phase II meetings with the FDA, expected in the second half of 2024.
DermBiont pivoted to small molecule topicals last year after investors showed little interest in microbiome-based therapies and the company cut its original lead dermatology gel while ending several other programs.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.